Targeting the Undruggable Proteome: The Small Molecules of My Dreams

Chemistry and Biology

Volumn 17, Issue 6, 2010, Pages 551-555

  Crews, Craig M ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR LIBRARY; PROTEOME;

ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY;

ANIMALS; DRUG DESIGN; GENETICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEOME; SMALL MOLECULE LIBRARIES;

EID: 77953699074     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.05.011     Document Type: Note

References (46)

1. Arakaki A.K., Tian W., and Skolnick J. High precision multi-genome scale reannotation of enzyme function by EFICAz. BMC Genomics 7 (2006) 315
2. Bargagna-Mohan P., Baek S.H., Lee H., Kim K., and Mohan R. Use of PROTACS as molecular probes of angiogenesis. Bioorg. Med. Chem. Lett. 15 (2005) 2724-2727
3. Bauer P.O., Goswami A., Wong H.K., Okuno M., Kurosawa M., Yamada M., Miyazaki H., Matsumoto G., Kino Y., Nagai Y., et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol. 28 (2010) 256-263
4. Cardenas M.E., Sanfridson A., Cutler N.S., and Heitman J. Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 16 (1998) 427-433
5. Clark M.A., Acharya R.A., Arico-Muendel C.C., Belyanskaya S.L., Benjamin D.R., Carlson N.R., Centrella P.A., Chiu C.H., Creaser S.P., Cuozzo J.W., et al. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nat. Chem. Biol. 5 (2009) 647-654
6. Gartner Z.J., Tse B.N., Grubina R., Doyon J.B., Snyder T.M., and Liu D.R. DNA-templated organic synthesis and selection of a library of macrocycles. Science 305 (2004) 1601-1605
7. Itoh Y., Ishikawa M., Naito M., and Hashimoto Y. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J. Am. Chem. Soc. 132 (2010) 5820-5826
8. James R.G., Biechele T.L., Conrad W.H., Camp N.D., Fass D.M., Major M.B., Sommer K., Yi X., Roberts B.S., Cleary M.A., et al. Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. Sci. Signal. 2 (2009) ra25
9. Kallander L.S., Lu Q., Chen W., Tomaszek T., Yang G., Tew D., Meek T.D., Hofmann G.A., Schulz-Pritchard C.K., Smith W.W., et al. 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J. Med. Chem. 48 (2005) 5644-5647
10. Kapoor T.M., and Mitchison T.J. Eg5 is static in bipolar spindles relative to tubulin: evidence for a static spindle matrix. J. Cell Biol. 154 (2001) 1125-1133
11. Kapoor T.M., Mayer T.U., Coughlin M.L., and Mitchison T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J. Cell Biol. 150 (2000) 975-988
12. Katsanakis K.D., Owen C., and Zoumpourlis V. JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. Anticancer Res. 22 (2002) 755-759
13. Kawasumi M., and Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J. Invest. Dermatol. 127 (2007) 1577-1584
14. Lennartz M.R. Phospholipases and phagocytosis: the role of phospholipid-derived second messengers in phagocytosis. Int. J. Biochem. Cell Biol. 31 (1999) 415-430
15. Marino Jr. J.P., Fisher P.W., Hofmann G.A., Kirkpatrick R.B., Janson C.A., Johnson R.K., Ma C., Mattern M., Meek T.D., Ryan M.D., et al. Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J. Med. Chem. 50 (2007) 3777-3785
16. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., and Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286 (1999) 971-974
17. Melkko S., Dumelin C.E., Scheuermann J., and Neri D. Lead discovery by DNA-encoded chemical libraries. Drug Discov. Today 12 (2007) 465-471
18. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8 (2009) 959-968
19. Nakanishi S., Yano H., and Matsuda Y. Novel functions of phosphatidylinositol 3-kinase in terminally differentiated cells. Cell. Signal. 7 (1995) 545-557
20. Overington J.P., Al-Lazikani B., and Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006) 993-996
21. Puppala D., Lee H., Kim K.B., and Swanson H.I. Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention. Mol. Pharmacol. 73 (2008) 1064-1071
22. Rodriguez-Gonzalez A., Cyrus K., Salcius M., Kim K., Crews C.M., Deshaies R.J., and Sakamoto K.M. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27 (2008) 7201-7211
23. Sachinidis A., Sotiriadou I., Seelig B., Berkessel A., and Hescheler J. A chemical genetics approach for specific differentiation of stem cells to somatic cells: a new promising therapeutical approach. Comb. Chem. High Throughput Screen. 11 (2008) 70-82
24. Sakamoto K.M., Kim K.B., Verma R., Ransick A., Stein B., Crews C.M., and Deshaies R.J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2 (2003) 1350-1358
25. Saporito M.S., Hudkins R.L., and Maroney A.C. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. 40 (2002) 23-62
26. Schlueter P.J., and Peterson R.T. Systematizing serendipity for cardiovascular drug discovery. Circulation 120 (2009) 255-263
27. Schneekloth Jr. J.S., and Crews C.M. Chemical approaches to controlling intracellular protein degradation. ChemBioChem 6 (2005) 40-46
28. Schneekloth Jr. J.S., Fonseca F.N., Koldobskiy M., Mandal A., Deshaies R., Sakamoto K., and Crews C.M. Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126 (2004) 3748-3754
29. Schneekloth A.R., Pucheault M., Tae H.S., and Crews C.M. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18 (2008) 5904-5908
30. Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., and Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94 (1997) 6099-6103
31. Siragusa M., Katare R., Meloni M., Damilano F., Hirsch E., Emanueli C., and Madeddu P. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ. Res. 106 (2010) 757-768
32. Soderholm J., Uehara-Bingen M., Weis K., and Heald R. Challenges facing the biologist doing chemical genetics. Nat. Chem. Biol. 2 (2006) 55-58
33. Soond D.R., Bjorgo E., Moltu K., Dale V.Q., Patton D.T., Torgersen K.M., Galleway F., Twomey B., Clark J., Gaston J.S., et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115 (2010) 2203-2213
34. Specht K.M., and Shokat K.M. The emerging power of chemical genetics. Curr. Opin. Cell Biol. 14 (2002) 155-159
35. Straight A.F., Cheung A., Limouze J., Chen I., Westwood N.J., Sellers J.R., and Mitchison T.J. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 299 (2003) 1743-1747
36. Sturgeon S.A., Jones C., Angus J.A., and Wright C.E. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur. J. Pharmacol. 587 (2008) 209-215
37. Takahashi-Yanaga F., and Sasaguri T. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J. Pharmacol. Sci. 109 (2009) 179-183
38. Ui M., Okada T., Hazeki K., and Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem. Sci. 20 (1995) 303-307
39. Verdine G.L., and Walensky L.D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13 (2007) 7264-7270
40. Wang W., Ma C., Mao Z., and Li M. JNK inhibition as a potential strategy in treating Parkinson's disease. Drug News Perspect. 17 (2004) 646-654
41. Wang J., Knight Z.A., Fiedler D., Williams O., Shokat K.M., and Pearce D. Activity of the p110-alpha subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport. Am. J. Physiol. Renal Physiol. 295 (2008) F843-F850
42. Wang J., Tucker L.A., Stavropoulos J., Zhang Q., Wang Y.C., Bukofzer G., Niquette A., Meulbroek J.A., Barnes D.M., Shen J., et al. Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor. Proc. Natl. Acad. Sci. USA 105 (2008) 1838-1843
43. Wheeler G.N., and Brandli A.W. Simple vertebrate models for chemical genetics and drug discovery screens: lessons from zebrafish and Xenopus. Dev. Dyn. 238 (2009) 1287-1308
44. Wu X., and Schultz P.G. Synthesis at the interface of chemistry and biology. J. Am. Chem. Soc. 131 (2009) 12497-12515
45. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48 Suppl 1 (2001) S20-S26
46. Zhu Z., and Cuozzo J. Review article: high-throughput affinity-based technologies for small-molecule drug discovery. J. Biomol. Screen. 14 (2009) 1157-1164